As of 2024-12-11, the Relative Valuation of Kiniksa Pharmaceuticals Ltd (KNSA) is (5.18) USD. This relative valuation is based on P/E multiples. With the latest stock price at 21.41 USD, the upside of Kiniksa Pharmaceuticals Ltd based on Relative Valuation is -124.2%.
The range of the Relative Valuation is (4.14) - (6.22) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 33.0x - 49.5x | 41.2x |
| Forward P/E multiples | 33.0x - 49.5x | 41.2x |
| Fair Price | (4.14) - (6.22) | (5.18) |
| Upside | -119.4% - -129.0% | -124.2% |
| Date | P/E |
| 2024-11-20 | -168.88 |
| 2024-11-19 | -165.77 |
| 2024-11-18 | -171.18 |
| 2024-11-15 | -169.51 |
| 2024-11-14 | -173.65 |
| 2024-11-13 | -180.10 |
| 2024-11-12 | -183.05 |
| 2024-11-11 | -183.45 |
| 2024-11-08 | -182.01 |
| 2024-11-07 | -183.21 |
| 2024-11-06 | -183.37 |
| 2024-11-05 | -175.40 |
| 2024-11-04 | -171.03 |
| 2024-11-01 | -178.95 |
| 2024-10-31 | -179.86 |
| 2024-10-30 | -183.21 |
| 2024-10-29 | -185.24 |
| 2024-10-28 | -219.67 |
| 2024-10-25 | -218.48 |
| 2024-10-24 | -214.34 |
| 2024-10-23 | -213.70 |
| 2024-10-22 | -213.30 |
| 2024-10-21 | -206.10 |
| 2024-10-18 | -209.08 |
| 2024-10-17 | -212.99 |
| 2024-10-16 | -209.56 |
| 2024-10-15 | -215.45 |
| 2024-10-14 | -212.03 |
| 2024-10-11 | -211.47 |
| 2024-10-10 | -202.95 |
| 2024-10-09 | -198.49 |
| 2024-10-08 | -194.83 |
| 2024-10-07 | -188.94 |
| 2024-10-04 | -194.91 |
| 2024-10-03 | -193.40 |
| 2024-10-02 | -195.31 |
| 2024-10-01 | -202.79 |
| 2024-09-30 | -198.97 |
| 2024-09-27 | -199.05 |
| 2024-09-26 | -190.77 |
| 2024-09-25 | -191.89 |
| 2024-09-24 | -194.67 |
| 2024-09-23 | -196.03 |
| 2024-09-20 | -204.15 |
| 2024-09-19 | -209.00 |
| 2024-09-18 | -201.20 |
| 2024-09-17 | -202.16 |
| 2024-09-16 | -200.33 |
| 2024-09-13 | -201.12 |
| 2024-09-12 | -194.99 |